Laurus Labs Ltd. News and Updates

Name: Latest research reports of Laurus Labs Ltd. authored by Keynote Capitals Ltd and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 3
Author: Keynote Capitals Ltd

Keep track of all breaking news on Laurus Labs Ltd. from all sources in a single place.

Load latest

Laurus Labs Ltd.

29 Jul 2024

591.90

0.53%

Laurus Labs Limited

Neutral: Laurus Labs Ltd.

Target

Keynote Capitals Ltd

Quarterly Update Q1FY25

Laurus Labs Ltd.'s price crossed below 100Day SMA today

Laurus Labs Ltd.

29 Jul 2024

591.90

0.53%

Gross margins improvement to fuel earnings growth

Buy: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs (LAURUSLABS) delivered a weak Q1FY25 due to lower revenue recorded in CDMO, FDFs and Bio and outperformance in generic APIs vs. our estimates.
The API outperformed due to strong growth in oncology and other APIs. Gross margins improved, however, due to improved products mix, process improvements in large value APIs and reduced raw material costs.

Laurus Labs Ltd. is trading below its 30 day SMA of 612.6

Laurus Labs Ltd.

26 Jul 2024

591.90

0.53%

Laurus Labs Q1 Results Review- Lower ARV Formulations, Reduced Operating Leverage Hurt Earnings: Motilal Oswal

NDTV Profit

The customer funding to the formulation facility for higher off-take further provides confidence on its efficient manufacturing capabilities, says the brokerages.

Laurus Labs Ltd. has gained 35.28% in the last 1 Year

Laurus Labs Ltd.

25 Jul 2024

591.90

0.53%

Laurus Labs Results Earnings Call for Q1FY25

Conference Call with Laurus Labs Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.

audio

Laurus Labs Ltd.

25 Jul 2024

591.90

0.53%

to see Rapid results content

Laurus Labs Ltd.

25 Jul 2024

591.90

0.53%

Lower ARV formulations and reduced operating leverage hurt earnings

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Labs (LAURUS) posted a weak 1QFY25 due to deviation in buying of ARV formulations and deferral of some orders in the other API segment.

Laurus Labs Ltd. has gained 35.28% in the last 1 Year

Laurus Labs Ltd.

04 Jul 2024

591.90

0.53%

Stock to buy today: Laurus Labs (437.6)

Business Line

The stock of Laurus Labs rebounded from the support at 425 this week, indicating a high probability of a rally to 475 in the near term

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

29 Apr 2024

591.90

0.53%

Laurus Labs Strategically Focused On Talent Acquisition And Programme Advancement, Says CEO Chava

NDTV Profit

Laurus Labs consolidated net profit declined 28.73% in the fourth quarter of financial year 2024, and it missed analysts' estimates.

Laurus Labs Ltd.'s price crossed above 50Day SMA today

Laurus Labs Ltd.

29 Apr 2024

591.90

0.53%

Laurus Labs Limited

Neutral: Laurus Labs Ltd.

Recommendation Target

Keynote Capitals Ltd

Quarterly Update Q4FY24

Laurus Labs Ltd. has gained 35.28% in the last 1 Year

Laurus Labs Ltd.

29 Apr 2024

591.90

0.53%

CDMO and Bio to drive profitability

Buy: Laurus Labs Ltd.

Recommendation Target

KRChoksey

Laurus Labs (LAURUSLABS) met our estimates on revenue, EBITDA margins and PAT front for both Q4FY24 and FY24; however, underperformed on GPM in Q4FY24 and marginally underperformed on the same in FY24. Notably, higher value CDMO and custom synthesis segment witnessed 3.5% Y-o-Y (+11.3% Q-o-Q) rise in revenue in Q4FY24 after 4 consecutive quarters of decline seen due to waning of high base effect.